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ABSTRACT
Aim: The humanized anti-CD52 monoclonal 
antibody alemtuzumab depletes lympho-
cytes and is currently used to treat relapsing 
multiple sclerosis. During treatment, anti-
alemtuzumab antibodies may develop and 
reduce effective lymphocyte depletion in 
future treatment cycles. Results: Alemtu-
zumab–Alexa Fluor 488 conjugate binding 
to the CHO-CD52 cell surface was inhibited by 
anti-alemtuzumab antibodies. Conclusion: In 
this proof-of-concept study, a CHO-CD52 cell 
line has been developed and used to detect 
the presence of anti-alemtuzumab neutral-
izing antibodies. This platform provides 
the basis of an assay for routine screening 
of serum for neutralizing antibodies from 
patients treated with alemtuzumab.
METHOD SUMMARY
We developed a competition assay between 
alemtuzumab and neutralizing antibodies to 
adherent CD52-expressing cells. The anti-
alemtuzumab antibodies inhibit alemtu-
zumab–Alexa Fluor 488 binding to cell 
surface CD52. Reduction in the fluorescence 
signal is proportional the amount of antidrug 
antibody in the serum sample.
LAY ABSTRACT
Therapeutic monoclonal antibodies 
are currently used for the treatment of 
numerous diseases and conditions, 
including relapsing multiple sclerosis, and 
are the most advanced targeted therapies 
available. However, they all have the 
potential to cause immunogenic reactions 
and generate antibodies that bind to the 
drug and reduce its therapeutic efficacy. 
As a result, patients do not receive the 
expected benefit from treatment, and the 
effect is cumulative with repeat dosing. 
The timely detection of antidrug antibodies 
has the potential to avoid these major risks. 
Here we describe a cell-based method for 
detecting anti-alemtuzumab neutralizing 
antibodies.
Campath-1 antigen (CD52) [1] is a highly 
negatively charged glycoprotein of 12 
amino acids anchored to glycosylphos-
phatidylinositol. It is widely expressed on 
the cell surface of immune cells such as 
natural killer cells, eosinophils, neutro-
phils, monocytes/macrophages, 
dendritic cells and mature lymphocytes, 
but not on the hematopoietic stem cells. 
Following T-cell activation, the soluble 
form of CD52 is released and binds to the 
sialic acid-binding Ig-like lectin-10 
(Siglec-10) receptor on T cells to suppress 
their function [2]. The soluble CD52 also 
inhibits Toll-like receptor and TNF 
receptor signaling to limit activation of 
NF-κB, suppressing the production of 
inflammatory cytokines by macro-
phages, monocytes and dendritic 
cells [3]. The surface-bound CD52 is the 
molecular target of a humanized 
monoclonal antibody, alemtuzumab, also 
known as Campath-1H or LEMTRADA® [4]. 
This antibody is used in treating chronic 
lymphocytic leukemia, for immunosup-
pression in organ transplantation, and in 
the treatment of patients with relapsing 
multiple sclerosis (pwRMS). In May 2014, 
the marketing authorization for alemtu-
zumab in pwRMS recommended a 
dosage of 12 mg/day administered by 
intravenous infusion for two treatment 
courses: an initial course lasting five 
consecutive days, followed 1 year later 
by a second course of three consecutive 
days. Recently, a third course of alemtu-
zumab treatment in pwRMS was 
approved by the European Medicines 
Agency [5]. Following two courses of 
treatment with alemtuzumab, antidrug 
antibodies (ADA) can be detected in 
pwRMS. These are binding antibodies in 
about 85% of patients and the majority 
of these – approximately 92% – are 
neutralizing antibodies (Nabs). Failure of 
lymphocyte depletion has been reported 
in pwRMS who tested positive for such 
Nabs [6,7]. To avoid potential treatment 
failure, it would be desirable to test for 
alemtuzumab ADA prior to subsequent 
courses of treatment. In this communi-
cation, we describe a novel cell-based 
ADA assay for the detection of alemtu-
zumab Nabs. We cloned the CD52 gene 
from Daudi cells then, using site-specific 
integration, we generated a stable 
adherent Chinese hamster ovary (CHO) 
cell line expressing the CD52 gene and 
developed an ADA assay to detect Nabs 
against alemtuzumab in an MS patient’s 
serum.
MATERIALS & METHODS
Cloning CD52 & plasmid construction
Daudi cells (human B lymphoblast cells, 
which express CD52) were maintained in 
RPMI 1640 medium supplemented with 
10% fetal bovine serum, 1% penicillin/
streptomycin and 1% L-glutamine at 37°C 
in a humidified incubator with 5% CO2. 
Total RNA was isolated from pelleted 
(3 × 106) Daudi cells using the RNeasy 
Mini Kit (Qiagen) and converted to cDNA 
using the ProtoScript® First Strand cDNA 
Synthesis Kit (NEB) with Oligo dT primer. 
Primers were designed to amplify CD52 
incorporating a Kozak [8] and overlap 
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sequences for Gibson assembly into the 
pcDNA5/FRT vector digested with NheI and 
NotI. The PCR amplification used Q5 
polymerase (NEB) and primers: (KzCD52F 
5′-TATAGGGAGACCCAAGCTGGCTAGCCAC-
CATGAAGCGCTTCCTC-3′ and CD52R 
5′-CGGGCCCTCTAGACTCGAGCGGCCGCT-
CAACTGAAGCAGAAGAGGTG-3′) with initial 
denaturing at 98°C for 30 s, then 32 cycles 
(98°C for 10 s, 65.3°C for 15 s, 72°C for 10 s), 
then 72°C for 2 min with a final hold at 4°C 
until analyzed. The plasmid was digested 
with NheI-HF and NotI-HF in CutSmart buffer 
(NEB). Both PCR product (241 bp) and vector 
restriction digest (4.96 kb) were resolved on 
1.2% agarose TAE gel, the DNA purified from 
excised bands, the plasmid assembled by 
Gibson assembly [9] and the NEB 5α cells 
transformed. Individual colonies were picked 
and plasmid isolated from overnight 
cultures. The sequence was determined by 
Sanger sequencing with a CMV forward 
sequencing primer (5′-CGCAAATGGGCGG-
TAGGCGTG-3′). The plasmid, designated 
pcDNA5/FRT KzCD52, was used in trans-
fecting CHO cells.
Cell transfection & selection
Prior to transfection, Flp-In™-CHO cells (Invit-
rogen) were maintained in RPMI medium 
supplemented with 10% fetal bovine serum, 
1% penicillin/streptomycin and 1% 
L-glutamine with zeocin selection. The day 
before transfection, the cells were treated 
with 1% trypsin-EDTA solution and seeded 
in a 24-well plate (4 × 104 cells per well in 
0.5 ml of complete growth medium) without 
zeocin. The next day, pOG44 plasmid 
(0.88 μg) and pcDNA5/FRT KzCD52 (0.08 μg) 
were mixed in 100 μl of Opti-MEM® I Reduced 
Serum Medium and Lipofectamine® LTX 
(Invitrogen) added (range 0.75–2.75 μl), 
mixed gently and incubated for 25 min at 
room temperature to form DNA–
Lipofectamine LTX complexes. The growth 
medium was removed from the cells and 
0.5 ml of complete growth medium added. 
Aliquots (100 μl) of the DNA–Lipofectamine 
LTX complexes were added directly to each 
well containing cells and mixed by gently 
rocking; the plate was incubated at 37°C in 
a CO2 incubator for 24 h before initiating 
hygromycin B (250 μg/ml) selection. The 
selection medium was changed every 
3–4 days until cell foci developed. The cells 
were detached and subjected to FACS to 
identify CD52-positive cells via staining with 
rat anti-CD52 FITC (Bio-Rad, MCA1642FT) 
and plated with limiting dilution and the 
process was repeated three times over 
6 months to ensure clonal selection. 
Expression of CD52 was confirmed by 
staining with rat anti-CD52-FITC, master 
stocks of CHO-CD52 cells expanded and 
aliquots stored in vapor phase liquid nitrogen 
until required.
Alemtuzumab–Alexa Fluor 488 conju-
gation
Alemtuzumab was labeled using the Rapid 
Lighting Link® Alexa Fluor® 488 kit following 
the instructions provided (Expedeon). Briefly, 
200 μg of alemtuzumab in 90 μl water was 
mixed with 10 μl of rapid modifier solution 
prior to adding to the lyophilized Alexa Fluor 
488 reagent. The mixture was incubated at 
ambient temperature in the dark for 30 min 
and the coupling reaction terminated by the 
addition of quench solution (10 μl), then left 
in the dark for 5 min prior to adding 90 μl 
phosphate-buffered saline (PBS). The 
alemtuzumab–Alexa Fluor 488 conjugate 
(1 μg/μl) was stored in the dark at 4°C until 
required.
CD52 detection on transfected cells
Flp-In CHO untransfected and Flp-In 
CHO-CD52 cells (5 × 104) were seeded on to 
glass coverslips in 24-well plates and left 
overnight before fixing with 1% paraformal-
dehyde for 10 min. The cells were washed 
twice with PBS and blocked with 10% goat 
serum in PBS for 30 min. The cells were 
incubated with either alemtuzumab–Alexa 
Fluor 488 (1:500) or its progenitor, the rat 
anti-CD52 FITC (1:500) (Bio-Rad MCA1642FT) 
diluted in 10% goat serum in PBS for 2 h, 
washed 3x with PBS prior to adding Vector-
shield with DAPI before capturing the images 
on fluorescence microscope (Leica DM5000) 
and processed using ImageJ.
Inhibition of alemtuzumab–Alexa Fluor 
488 binding to Flp-In CHO-CD52 cells 
using an anti-alemtuzumab monoclonal 
antibody
Experiments were performed in accordance 
with the guidelines of the Declaration of 
Helsinki. The participants gave written 
informed consent for blood samples for use 
in research on the institutional NHS consent 
form. Flp-In CHO-CD52 cells were seeded in 
Falcon® 96-well Black/Clear Flat Bottom 
TC-treated Imaging Microplate plates at 
3 × 103 cells per well and left for 3 days before 
fixing with 1% paraformaldehyde for 10 min. 
The wells were blocked just prior to use, as 
described above. Initially, sera from patients 
diagnosed with MS prior to alemtuzumab 
treatment (n = 2) and from healthy control 
subjects (n = 2) were diluted 1/10 in human 
control serum (Merck H4522) and spiked 
with 1.5 μl anti-alemtuzumab (Bio-Rad 
HCA199) (1.5 μg/65 μl) or human control 
serum. Inhibition of alemtuzumab-Alexa 
Fluor 488 binding to the CHO-CD52 cells was 
determined. An equal volume of each sample 
was added to the alemtuzumab–Alexa Fluor 
488 conjugate diluted 1:500 in 10% goat 
serum in PBS (final concentration ∼1 ng 
alemtuzumab/μl), then the mixture was 
incubated at room temperature in the dark 
for 2 h. The serum/alemtuzumab–Alexa 
Fluor 488 (40 μl/40 ng alemtuzumab–Alexa 
Fluor 488) was added to the wells in triplicate, 
then incubated for 2 h before washing with 
PBS and adding Vectashield with DAPI for 
5 min in the dark, washing as before, 
measuring the total fluorescence on the 
Clariostar plate reader and the data plotted 
using GraphPad Prism. In addition, the sera 
were diluted 1/10 in human control serum 
(Merck H4522) and spiked with 1.0 μl anti-
alemtuzumab (Bio -Rad HCA199) 
(1.0 μg/100 μl) and serially threefold diluted 
in human control serum. Inhibition of alemtu-
zumab–Alexa Fluor 488 binding to the 
CHO-CD52 cells was determined for each 
dilution as described.
Intra- & interassay variation
When performing the assay, human control 
serum aliquots (Merck H4522) with and 
without the alemtuzumab–Alexa Fluor 488 
were used to determine the maximum and 
minimum fluorescence (background) signal. 
The inter- and intra-assay coefficients of 
variation of the maximum and minimum 
fluorescence were based on values from six 
replicates on four plates.
Cell-based assay for the detection of 
anti-alemtuzumab Nabs
Blood samples from consented MS patients 
treated with alemtuzumab were collected 
and processed in March 2016 and 2017 and 
the serum stored at -20°C until required. For 
experiments on the IN Cell Analyzer (INCA 
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2200), Flp-In CHO-CD52 cells were seeded 
into a Falcon 96-well Black/Clear Flat Bottom 
TC-treated Imaging Microplate; plates were 
prepared as described above. Serum from a 
patient treated with alemtuzumab was taken 
5 months after the first round of treatment 
(sample 2016) and the second round of 
treatment (sample 2017) and assayed for 
anti-alemtuzumab binding antibodies using 
an in-house anti-alemtuzumab assay [10]. 
Human serum (Merck H4522) was used as 
a blank control and diluent for the patient 
serum. The patient sera were serially 
threefold diluted (neat to 1:729) and 65 μl of 
each dilution added to 65 μl of alemtu-
zumab–Alexa Fluor 488 conjugate diluted 
1:500 in 10% goat serum and incubated at 
room temperature in the dark for 2 h. The 
sera/alemtuzumab–Alexa Fluor 488 
(40 μl/∼40 ng alemtuzumab) was added to 
the wells in triplicate, incubated for 2 h before 
washing with PBS and adding 0.1 ml HCS 
CellMask™ Deep Red Stain for 90 min in the 
dark washing, adding Vectashield with DAPI 
in the dark for 5 min, washing again before 
capturing the images on INCA2200 (GE). 
Images were analyzed using the IN Cell 
Developer Toolbox (GE) to quantify the 
number of cells with fluorescence foci and 
the data plotted using GraphPad Prism to 
calculate the percentage of cells with 
fluorescence foci and dilution required for 
50% inhibition (ID50).
RESULTS & DISCUSSION
Daudi cells were used as a source of human 
CD52 transcripts. Two specific primers 
(KzCD52F and CD52R) were designed to 
amplify CD52 and introduce a Kozak 
sequence and overlap sequences to facil-
itate Gibson assembly into pcDNA 5/FRT 
restricted with NheI and NotI. Following 
reverse transcription and PCR, a product of 
241 bp obtained. Successful cloning was 
confirmed by Sanger sequencing of the final 
construct pcDNA5/FRT-CD52. The 
sequences flanking the CD52 were present 
and the nucleotide and open reading frame 
sequences were confirmed by NCBI BLAST 
search (GenBank X67699.1 and AAH00644.1, 
respectively). The plasmid pcDNA 5/FRT 
CD52 sequence is available upon request.
The pcDNA 5/FRT CD52 plasmid was 
transfected into CHO Flp-In™ cells using 
Lipofectamine. The cells were maintained 
on hygromycin B selection, single cell 
sorted with plating at limiting dilution every 
2 months for 6 months until cells derived 
from a single well were >95% positive in 
the FACS (Figure 1A–C). Untransfected 
Flp-In CHO and Flp-In CHO-CD52 cells were 
seeded on to glass coverslips and probed 
with rat anti-CD52-FITC and alemtuzumab 
conjugated to Alexa Fluor 488. As shown in 
Figure 1D, only the transfected cells exhibited 
staining with both anti-CD52 antibodies. 
A competitive microtiter plate assay to 
detect anti-alemtuzumab antibodies was set 
up as shown on the schematic Figures 2A & 
B. Briefly, in the absence of Nabs the fluores-
cence signal would be maximal (Figure 2A) 
and in the presence of Nabs signal would 
be reduced (Figure 2B). An anti-alemtu-
zumab monoclonal antibody was used to 
spike either pretreatment MS patient sera 
or healthy control sera and the inhibition of 
alemtuzumab–Alexa Fluor 488 binding to 
CD52 determined (Figure 2C). The addition 
of anti-alemtuzumab reduced the fluores-
cence signal in both spiked MS and healthy 
control serums. Moreover, the inhibitory 
activity could be titrated by serial dilution 
(Figure 2D). To determine the inter- and 
intra-assay variation, replicates (n = 6) of 
the maximum and minimum binding were 
determined on four experiments (Figure 2E). 
The intra-assay coefficients of variation 
were between 10 and 7.2% for the maximum 
binding, and between 3.5 and 1.6% for the 
minimum binding. The interassay coeffi-
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Figure 1. Flow cytometry confirmed the expression of CD52 on transfected Chinese hamster 
ovary cells. (A) Untransfected CHO cells. (B) CHO-CD52 cells. (C) Frequency of CHO-CD52 positive 
cells (95.3%). (D) The presence of CD52 was further confirmed in the transfected cells by staining 
for CD52 using either the rat anti-CD52-FITC or Alemtuzumab–Alexa Fluor 488. The untrans-
fected controls were included. CD52 expression is in green and the nuclear staining in blue. Scale 
bar = 20 μm.
CHO: Chinese hamster ovary.
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cient of variation was 9.6% for the maximum 
binding and 7.9% for the minimum binding 
(Table 1). 
With the alemtuzumab-treated MS 
patient samples, the reduction in fluores-
cence could be titrated (Figure 3A) and 
the ID50 determined (Figure 3B). The neat 
MS patient sera completely inhibited the 
binding of alemtuzumab to the CHO-CD52 
cell, whereas the control human serum did 
not. Upon dilution, the 2016 serum sample 
had ID50 at approximately 1/8 dilution and 
the 2017 serum sample required further 
dilution to approximately 1/136 for equiv-
alent inhibition, as shown in Figures 3A & B. 
Alemtuzumab mediates depletion of 
lymphocytes in vivo by antibody-dependent 
cellular cytotoxicity (ADCC), complement-
dependent cytotoxicity (CDC) [11–15] and is 
used in the treatment of RMS [16]. In Phase III 
studies, alemtuzumab treatment beyond the 
initial two courses was offered if a relapse 
occurred or if a patient accumulated two or 
more unique MRI lesions (either gadolinium-
enhancing lesions and/or new or enlarging 
T2 lesions). If patients have developed Nabs, 
the efficacy of the third and subsequent 
rounds of alemtuzumab treatment may be 
compromised. Retreatment with alemtu-
zumab beyond the initial two courses of 
therapy has been approved by the EMA [5]. 
A test to determine the presence and 
relative levels of neutralizing ADA may help 
to stratify patients before proceeding with 
further treatment with alemtuzumab.
The target for alemtuzumab, CD52, has 
been cloned and expressed in Jurkat and 
CHO cell line by several groups for a variety of 
functional studies [17], for use as an antigen 
and for soluble CD52 production [18], and in 
NS0 cells for use as an immunogen and in 
a cell-based ELISA [19]. Here we generated 
a stable recombinant adherent CHO cell 
line expressing human CD52 for use with 
alemtuzumab–Alexa 488 in a competitive 
binding assay to detect ADA Nabs. For 
proof of concept, we determined whether: 
a commercially available anti-alemtuzumab 
monoclonal antibody could inhibit the binding 
to the CHO-CD52 cells when spiked into 
serum and this inhibitory activity could be 
titrated. The addition of anti-alemtuzumab 
reduced the fluorescence signal in both MS 
and healthy sera by between 70 and 100% 
(Figure 2C). Moreover, spiking MS patient 
and healthy control serum with ADA and 
assaying serial dilutions demonstrated that 
the inhibitory activity titrated out with 50% 
inhibition at 1 ng/ml ADA, equimolar with 
the alemtuzumab–Alexa 488 concentration 
used in the assay (Figure 2D). The maximum 
and minimum fluorescence signals within 
and across experiments were determined 
(Figure 2E). The maximum signal intra-assay 
coefficients of variation were 7.2–10% with an 
interassay value of 9.6%. The minimum intra-
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Figure 2. Schematic of the assay format. (A) In the absence of ADA, Alemtuzumab–Alexa Fluor 488 
binds to the cells resulting in a high fluorescence signal. (B) In the presence of neutralizing ADA, the 
Alemtuzumab–Alexa Fluor 488 is prevented from binding to the cells, resulting in a loss of fluores-
cence. (C) Serum samples from an MS patient and healthy individuals not treated with alemtu-
zumab were spiked with anti-alemtuzumab and assayed for inhibiting alemtuzumab–Alexa Fluor 
488 binding to CHO-CD52 cells using fluorescence measurement on a Clariostar Plus plate reader 
and the data plotted using GraphPad Prism. (D) Serum samples from an MS patient and a healthy 
individual not treated with alemtuzumab were spiked with anti-alemtuzumab, threefold serially 
diluted and assayed for inhibiting alemtuzumab–Alexa Fluor 488 binding to CHO-CD52 cells using 
fluorescence measurement on a Clariostar Plus plate reader and the data plotted using GraphPad 
Prism. (E) The maximum and minimum fluorescence (n = 6) were determined in four experiments, 
and the data plotted using GraphPad Prism.
ADA: Antidrug antibody; CHO: Chinese hamster ovary; MS: Multiple sclerosis.
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assay signal was found to be 1.6–3.5% with 
an interassay value of 7.9% (Table 1). These 
values are within the acceptable range.
In this study, we investigated sera from 
a patient who had received two rounds of 
treatment following the approved schedule. 
We had previously determined that the serum 
sample contained binding ADA against the 
variable heavy (VH) and light (VL) domains 
of alemtuzumab  . The appearance of ADA 
following the second round of treatment is 
common [7]; however, due to the sensitivity 
of this assay, we could detect the presence 
of Nabs 5 months after the first infusion – 
albeit at a lower titer, but significantly above 
the level of detection. Furthermore, the titer 
increases 17-fold following the second 
infusion of drug (Figure 2F & G). Whether 
5 months postinfusion is the optimal point 
for sampling remains to be determined.
Ideally, for pwRMS on alemtuzumab to be 
considered for further treatment, the levels of 
ADA 1 month before the proposed treatment 
should be determined. If detectable levels 
are present, the treatment should be delayed 
and the ADA titers monitored (to fall below 
detection) prior to treatment. Alterna-
tively, patients may benefit from plasma 
exchange to lower the ADA prior to drug 
administration. Although speculative, such 
an approach could extend the therapeutic 
utility of alemtuzumab. The availability of a 
cell-based assay for the rapid detection of 
anti-alemtuzumab Nabs that requires 65 μl 
of serum provides an opportunity to screen 
patients in advancement of treatment, 
to monitor ADA levels and determine the 
appropriate timing for drug administration 
for maximum patient benefit.
Adherent cell lines expressing the thera-
peutic antibody targets provide a general 
cost-effective, rapid, quantitative data 
collection platform for developing assays 
to detect Nabs on the INCA 2200 instrument 
or the Clariostar Plus plate reader. The 
approach described here could be adapted 
for the detection of ADA Nabs against other 
therapeutic antibodies used in MS that 
target cell surface antigens such as CD20 
and CD49d.
CONCLUSION
In this proof-of-concept study, an adherent 
cell-based method for assaying for the 
presence of anti-alemtuzumab Nabs in sera 
from a patient treated with alemtuzumab 
was developed. The method utilizes a stable 
adherent CHO cell line expressing human 
CD52, and a competition assay between the 
antidrug antibody and alemtuzumab labeled 
with Alexa Fluor 488. The method success-
fully detected the presence of Nabs that 
inhibited the binding of alemtuzumab to the 
CHO-CD52 cells. The assay should be used 
to monitor patients on this drug for the 
emergence of Nabs and to correlate the 
inhibitory activity with the lymphocyte 
counts as an indicator of drug efficacy.
FUTURE PERSPECTIVE
Over the next decade, many more thera-
peutics – either as human monoclonal 
antibodies or based on human monoclonal 
binding sites (i.e., CAR-T cell therapies) – will 
enter the clinic for unmet needs. The 
frequent administration of the biologic agent 
required for some chronic conditions will 
trigger antibody responses in some 
individuals, reducing the drug efficacy. 
Testing for the emergence of ADA, and in 
particular neutralizing ADA, will be imper-
ative. The testing may be further developed 
for use in point-of-care devices or for 
monitoring at home.
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Figure 3. The serum samples from a patient were threefold serially diluted and assayed from neat to 
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